12(S)-hydroxyeicosatetraenoic acid levels link to coronary artery disease in Type 2 diabetic patients

Journal of Endocrinological Investigation

Volumn 36, Issue 6, 2013, Pages 385-389

  Zhang, H J ^a   Sun, C H ^b   Kuang, H Y ^a   Jiang, X Y ^a   Liu, H L ^a   Hua, W F ^c   Liu, Z J ^c   Zhou, H ^d   Sui, H ^b   Qi, R ^b  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Zunhua People's Hospital   (China)

^d People's Liberation Army 93383 Hospital   (China)

Author keywords

12(S) Hydroxyeicosatetraenoic acid; Coronary artery disease; Type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HYDROXYICOSATETRAENOIC ACID; 12 HYDROXYICOSATETRAENOIC ACID;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; DIABETIC ANGIOPATHY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; RISK FACTOR; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ADULT; AGED; BLOOD PRESSURE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84881472244     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8654     Document Type: Article

References (32)

1. Yan X, Sano M, Lu L, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2010, 9: 70.
2. Pu LJ, Lu L, Xu XW, et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006, 5: 27.
3. Milicevic Z, Raz I, Beattie SD, et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008, 31 (Suppl 2): S155-60.
4. Zaccardi F, Pitocco D, Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009, 25: 199-207.
5. Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol 2009, 53: S28-34.
6. Malik S, Wong ND. Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis. Expert Rev Cardiovasc Ther 2009, 7: 273-80.
7. El-Mesallamy H, Hamdy N, Suwailem S, Mostafa S. Oxidative stress and platelet activation: markers of myocardial infarction in type 2 diabetes mellitus. Angiology 2010, 61: 14-8.
8. Yeung J, Holinstat M. 12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovasc Hematol Agents Med Chem 2011, 9: 154-64.
9. Suzuki N, Hishinuma T, Saga T, et al. Determination of urinary 12(S)-hydroxyeicosatetraenoic acid by liquid chromatography-tandem mass spectrometry with column-switching technique: sex difference in healthy volunteers and patients with diabetes mellitus. J Chromat B Analyt Technol Biomed Life Sci 2003, 783: 383-9.
10. Limor R, Kaplan M, Sharon O, et al. Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. J Cell Biochem 2009, 108: 1203-10.
11. Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012, 56: 118-29.
12. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26: 3160-7.
13. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113: e463-654.
14. Lenzen MJ, Boersma E, Bertrand ME, et al. European Society of Cardiology. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005, 26: 1169-79.
15. Xu ZG, Yuan H, Lanting L, et al. Products of 12/15-lipoxygenase upregulate the angiotensin II receptor. J Am Soc Nephrol 2008, 19: 559-69.
16. Xu ZG, Miao LN, Cui YC, Jia Y, Yuan H, Wu M. Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli. Nephrol Dial Transplant 2009, 24: 1744-52.
17. Reddy MA, Thimmalapura PR, Lanting L, Nadler JL, Fatima S, Natarajan R. The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. Mediation of angiotensin II effects. J Biol Chem 2002, 277: 9920-8.
18. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 1997, 273: H2224-31.
19. Nazarewicz RR, Zenebe WJ, Parihar A, et al. 12(S)- hydroperoxyeicosatetraenoic acid (12-HETE) increases mitochondrial nitric oxide by increasing intramitochondrial calcium. Arch Biochem Biophys 2007, 468: 114-20.
20. Guo QY, Miao LN, Li B, et al. Role of 12-lipoxygenase in decreasing P-cadherin and increasing angiotensin II type 1 receptor expression according to glomerular size in type 2 diabetic rats. Am J Physiol Endocrinol Metab 2011, 300: E708-16.
21. Jain M, Ratheesh A, Gude RP. Pentoxifylline inhibits integrin-mediated adherence of 12(S)-HETE and TNFalpha-activated B16F10 cells to fibronectin and endothelial cells. Chemotherapy 2010, 56: 82-8.
22. Pearson T, Warren AY, Barrett DA, Khan RN. Detection of EETs and HETE-generating cytochrome P-450 enzymes and the effects of their metabolites on myometrial and vascular function. Am J Physiol Endocrinol Metab 2009, 297: E647-56.
23. Jiang P, Dai W, Yan S, et al. Biomarkers in the early period of acute myocardial infarction in rat serum and protective effects of Shexiang Baoxin Pill using a metabolomic method. J Ethnopharmacol 2011, 138: 530-6.
24. Liu Y, Wang H, Zhu Y, Chen L, Qu Y, Zhu Y. The protective effect of nordihydroguaiaretic acid on cerebral ischemia/reperfusion injury is mediated by the JNK pathway. Brain Res 2012, 1445: 73-81.
25. Al-Shabrawey M, Mussell R, Kahook K, et al. Increased expression and activity of 12-lipoxygenase in oxygen-induced ischemic retinopathy and proliferative diabetic retinopathy: implications in retinal neovascularization. Diabetes 2011, 60: 614-24.
26. Reddy MA, Sahar S, Villeneuve LM, Lanting L, Natarajan R. Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2009, 29: 387-93.
27. González-Núñez D, Claria J, Rivera F, Poch E. Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 2001, 37: 334-8.
28. Dołegowska B, Błogowski W, Kedzierska K, et al. Platelets arachidonic acid metabolism in patients with essential hypertension. Platelets 2009, 20: 242-9.
29. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL. 12-Lipoxygenase products reduce insulin secretion and {beta}-cell viability in human islets. J Clin Endocrinol Metab 2010, 95: 887-93.
30. Abdel-Rahman EM, Abadir PM, Siragy HM. Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors. Am J Physiol Regul Integr Comp Physiol 2008, 295: R1473-8.
31. Prasad KM, Thimmalapura PR, Woode EA, Nadler JL. Evidence that increased 12-lipoxygenase expression impairs pancreatic beta cell function and viability. Biochem Biophys Res Commun 2003, 308: 427-32.
32. Antonipillai I, Nadler J, Vu EJ, Bughi S, Natarajan R, Horton R. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 1996, 81: 1940-5.